Targeting key signalling pathways in oesophageal adenocarcinoma: A reality for personalised medicine?

World Journal of Gastroenterology

Volumn 17, Issue 23, 2011, Pages 2781-2790

  Keld, Richard R ^a,b   Ang, Yeng S ^a,b  

^a ROYAL ALBERT EDWARD INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Map and pi3 kinase pathways; Nuclear factor b pathways; Oesophageal adenocarcinoma; Pathway; Signalling pathways; Transcription factors; Transforming growth factor ; Tyrosine kinase receptors; Wnt signalling

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; BECAZUTUMAB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; FOLINIC ACID; GASTRIN; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SMAD PROTEIN; SOMATOMEDIN; SORAFENIB; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BARRETT ESOPHAGUS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CENTRAL VENOUS CATHETERIZATION; COLORECTAL CARCINOMA; DNA METHYLATION; DNA REPLICATION; DNA TRANSCRIPTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; EDITORIAL; ENZYME INHIBITION; ENZYME REGULATION; ESOPHAGEAL ADENOCARCINOMA; GENE EXPRESSION; GENE TARGETING; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; SURVIVAL TIME; TREATMENT FAILURE;

EID: 79959673065     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i23.2781     Document Type: Editorial

References (84)

1. Office for National Statistics. Cancer Statistics registrations: Registrations of cancer diagnosed in 2006, England. Series MB1 No. 37. 2008
2. Adams R, Morgan M, Mukherjee S, Brewster A, Maughan T, Morrey D, Havard T, Lewis W, Clark G, Roberts S, Vachtseva-nos L, Leong J, Hardwick R, Carey D, Crosby T. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol 2007; 33: 307-313
3. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053
4. el-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 2002; 31: 421-440, 8
5. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther 2003; 17: 655-664
6. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211
7. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margan-tinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1413-1417, 1417.e1-2
8. Solaymani-Dodaran M, Logan RF, West J, Card T, Coup-land C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53: 1070-1074
9. Rubenstein JH, Sonnenberg A, Davis J, McMahon L, In-adomi JM. Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc 2008; 68: 849-855
10. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarci-noma: a population-based study with temporal trends. Am J Gastroenterol 2009; 104: 1356-1362
11. Wang VS, Hornick JL, Sepulveda JA, Mauer R, Poneros JM. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest Endosc 2009; 69: 777-783
12. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 237-249
13. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267
14. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-1664
15. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Ox-aliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4-12
16. Sinha BK, Politi PM. Anthracyclines. Cancer Chemother Biol Response Modif 1990; 11: 45-57
17. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the frst of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646-662
18. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
19. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Teb-butt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fuorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976-1983
20. 2nd Annual Report of the National Oesophago-Gastric Cancer Audit 2009. The NHS Information Centre IC23090209
21. Kulke MH, Wu B, Clark JW, Enzinger PC, Lynch TJ, Vinci-tore M, Michelini A, Fuchs CS. A phase II study of doxoru-bicin, cisplatin, and 5-fuorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest 2006; 24: 229-234
22. Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 2003; 89: 2045-2050
23. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesopha-geal cancer. N Engl J Med 2006; 355: 11-20
24. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-1733
25. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730
26. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251: 1-16
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
28. Alberts BJ, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4 ed. Garland Science, 2002
29. Chaganti RS. Signifcance of chromosome change to hema-topoietic neoplasms. Blood 1983; 62: 515-524
30. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-599
31. Dunn KL, Espino PS, Drobic B, He S, Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol 2005; 83: 1-14
32. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69: 565-572
33. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002; 12: 9-18
34. Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 2007; 274: 60-68
35. Soma T, Kaganoi J, Kawabe A, Kondo K, Tsunoda S, Imam-ura M, Shimada Y. Chenodeoxycholic acid stimulates theprogression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer. Int J Cancer 2006; 119: 771-782
36. Keld R, Guo B, Downey P, Gulmann C, Ang YS, Sharrocks AD. The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol Cancer 2010; 9: 313
37. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphoryla-tion of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247-254
38. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, Löning T. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005; 92: 2206-2215
39. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, Reich R. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 2003; 91: 160-172
40. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168-1171
41. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510
42. Phillips WA, Russell SE, Ciavarella ML, Choong DY, Montgomery KG, Smith K, Pearson RB, Thomas RJ, Campbell IG. Mutation analysis of PIK3CA and PIK3CB in esopha-geal cancer and Barrett's esophagus. Int J Cancer 2006; 118: 2644-2646
43. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272
44. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461-6468
45. Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lan-schot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008; 98: 1102-1108
46. Kleespies A, Bruns CJ, Jauch KW. Clinical signifcance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie 2005; 28: 281-288
47. Iravani S, Zhang HQ, Yuan ZQ, Cheng JQ, Karl RC, Jove R, Coppola D. Modifcation of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol 2003; 34: 975-982
48. Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T. Clinical signifcance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008; 74: 76-83
49. Gockel I, Moehler M, Frerichs K, Drescher D, Trinh TT, Duen-schede F, Borschitz T, Schimanski K, Biesterfeld S, Herzer K, Galle PR, Lang H, Junginger T, Schimanski CC. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep 2008; 20: 845-850
50. Yoshino M, Ishiwata T, Watanabe M, Matsunobu T, Komine O, Ono Y, Yamamoto T, Fujii T, Matsumoto K, Tokunaga A, Naito Z. Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol 2007; 31: 721-728
51. Tanaka K, Mohri Y, Nishioka J, Ohi M, Yokoe T, Miki C, Tonouchi H, Nobori T, Kusunoki M. Neurotrophic receptor, tropomyosin-related kinase B, as a chemoresistant marker in oesophageal cancer. Clin Oncol (R Coll Radiol) 2009; 21: 362-363
52. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548-5557
53. Tan X, Egami H, Abe M, Nozawa F, Hirota M, Ogawa M. Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol 2005; 58: 1242-1248
54. Albino AP, Le Strange R, Oliff AI, Furth ME, Old LJ. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 1984; 308: 69-72
55. Sutter AP, Höpfner M, Huether A, Maaser K, Scherübl H. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 2006; 118: 1814-1822
56. Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squa-mous cell carcinoma. Br J Cancer 2007; 97: 494-501
57. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, Harrison R, Jankowski J. A phase II study of geftinib monotherapy in advanced esophageal adenocar-cinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007; 13: 5869-5875
58. Lordick F, von Schilling C, Bernhard H, Hennig M, Breden-kamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003; 89: 630-633
59. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR. Phase II study of irinote-can and 5-fuorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69
60. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon Cajal S, Baselga J. Pharmacodynamic studies of geftinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24: 4309-4316
61. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G. Predictive factors for outcome in a phase II study of gef-tinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-1619
62. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Bene-detti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL. Phase II trial of erlotinib in gastro-esophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927
63. Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A. Phase I study of epirubicin, cisplatin and capecitabine plus matu-zumab in previously untreated patients with advanced oe-sophagogastric cancer. Br J Cancer 2008; 99: 868-874
64. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and ce-tuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
65. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Rob-itaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and beneft from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765
66. Hollstein MC, Peri L, Mandard AM, Welsh JA, Montesano R, Metcalf RA, Bak M, Harris CC. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res 1991; 51: 4102-4106
67. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA. Phase II study of cetuximab in combination with FOLFIRI in patients withuntreated advanced gastric or gastroesophageal junction ade-nocarcinoma (FOLCETUX study). Ann Oncol 2007; 18: 510-517
68. Safran H, Dipetrillo T, Akerman P, Ng T, Evans D, Stein-hoff M, Benton D, Purviance J, Goldstein L, Tantravahi U, Kennedy T. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overex-pressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 405-409
69. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of iri-notecan, cisplatin, and bevacizumab in patients with meta-static gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206
70. Clément G, Jablons DM, Benhattar J. Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets 2007; 11: 375-389
71. Clément G, Braunschweig R, Pasquier N, Bosman FT, Ben-hattar J. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006; 25: 3084-3092
72. Onwuegbusi BA, Aitchison A, Chin SF, Kranjac T, Mills I, Huang Y, Lao-Sirieix P, Caldas C, Fitzgerald RC. Impaired transforming growth factor beta signalling in Barrett's carci-nogenesis due to frequent SMAD4 inactivation. Gut 2006; 55: 764-774
73. Peters CR, Hardwick J, Hardwick R, Zhang J, Vowler C, Save S, O'donovan V, Caldas M, Alderson C, Fitzgerald D. On Behalf Of The OCCAMS Study Group, A seven gene signiture outperforms clinical features at predicting survival in oesophageal adenocarcinoma World Congress of Gastro-enterology/UEGW, London, 2009
74. Ogasa M, Miyazaki Y, Hiraoka S, Kitamura S, Nagasawa Y, Kishida O, Miyazaki T, Kiyohara T, Shinomura Y, Matsu-zawa Y. Gastrin activates nuclear factor kappaB (NFkappaB) through a protein kinase C dependent pathway involving NFkappaB inducing kinase, inhibitor kappaB (IkappaB) ki-nase, and tumour necrosis factor receptor associated factor 6 (TRAF6) in MKN-28 cells transfected with gastrin receptor. Gut 2003; 52: 813-819
75. Abdel-Latif MM, Kelleher D, Reynolds JV. Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J Surg Res 2009; 153: 172-180
76. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 4456-4462
77. Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J, Schmidt CM. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice. J Gastrointest Surg 2008; 12: 30-37
78. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 2010; 21: 326-332
79. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ. Phase II trial of sorafenib plus interferon alfa-2b as frst- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25: 3288-3295
80. Delgado JS, Mustafi R, Yee J, Cerda S, Chumsangsri A, Dougherty U, Lichtenstein L, Fichera A, Bissonnette M. Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. Dig Dis Sci 2008; 53: 3055-3064
81. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Ka-poor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
82. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Karikó K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J. Sequence- and target-independent angiogen-esis suppression by siRNA via TLR3. Nature 2008; 452: 591-597
83. Grünweller A, Hartmann RK. RNA interference as a gene-specifc approach for molecular medicine. Curr Med Chem 2005; 12: 3143-3161
84. Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, Zhang C, Save V, O'Donovan M, Rassl D, Alder-son D, Caldas C, Fitzgerald RC. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010; 139: 1995-2004.e15